Publicación:
Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: Results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants

Página de artículo simple
dc.contributor.authorBosch, Jackie
dc.contributor.authorLonn, Eva M.
dc.contributor.authorJung, Hyejung
dc.contributor.authorZhu, Jun
dc.contributor.authorLiu, Lisheng
dc.contributor.authorLopez-Jaramillo, Patricio
dc.contributor.authorPais, Prem
dc.contributor.authorXavier, Denis
dc.contributor.authorDiaz, Rafael
dc.contributor.authorDagenais, Gilles
dc.contributor.authorDans, Antonio
dc.contributor.authorAvezum, Alvaro
dc.contributor.authorPiegas, Leopoldo S.
dc.contributor.authorParkhomenko, Alexander
dc.contributor.authorKeltai, Kati
dc.contributor.authorKeltai, Matya
dc.contributor.authorSliwa, Karen
dc.contributor.authorHeld, Claus
dc.contributor.authorPeters, Ronald J.G.
dc.contributor.authorLewis, Basil S.
dc.contributor.authorJansky, Petr
dc.contributor.authorYusoff, Khalid
dc.contributor.authorKhunti, Kamlesh
dc.contributor.authorToff, William D.
dc.contributor.authorReid, Christopher M.
dc.contributor.authorVarigos, John
dc.contributor.authorJoseph, Philip
dc.contributor.authorLeiter, Lawrence A.
dc.contributor.authorYusuf, Salim
dc.contributor.authorThe Heart Outcomes Prevention Evaluation (HOPE)-3 Investigators
dc.contributor.researchgroupMasiraspa
dc.date.accessioned2022-02-23T13:35:46Z
dc.date.available2022-02-23T13:35:46Z
dc.date.issued2021-08-14
dc.descriptionDigitalspa
dc.description.abstractAims. Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) events by 24% in 12 705 participants at intermediate CV risk after 5.6 years. There was no benefit of blood pressure (BP) lowering treatment in the overall group, but a reduction in events in the third of participants with elevated systolic BP. After cessation of all the trial medications, we examined whether the benefits observed during the active treatment phase were sustained, enhanced, or attenuated. Methods and results. After the randomized treatment period (5.6 years), participants were invited to participate in 3.1 further years of observation (total 8.7 years). The first co-primary outcome for the entire length of follow-up was the composite of myocardial infarction, stroke, or CV death [major adverse cardiovascular event (MACE)-1], and the second was MACE-1 plus resuscitated cardiac arrest, heart failure, or coronary revascularization (MACE-2). In total, 9326 (78%) of 11 994 surviving Heart Outcomes Prevention Evaluation (HOPE)-3 subjects consented to participate in extended follow-up. During 3.1 years of post-trial observation (total follow-up of 8.7 years), participants originally randomized to rosuvastatin compared with placebo had a 20% additional reduction in MACE-1 [95% confidence interval (CI), 0.64–0.99] and a 17% additional reduction in MACE-2 (95% CI 0.68–1.01). Therefore, over the 8.7 years of follow-up, there was a 21% reduction in MACE-1 (95% CI 0.69–0.90, P = 0.005) and 21% reduction in MACE-2 (95% CI 0.69–0.89, P = 0.002). There was no benefit of BP lowering in the overall study either during the active or post-trial observation period, however, a 24% reduction in MACE-1 was observed over 8.7 years. Conclusion. The CV benefits of rosuvastatin, and BP lowering in those with elevated systolic BP, compared with placebo continue to accrue for at least 3 years after cessation of randomized treatment in individuals without cardiovascular disease indicating a legacy effectspa
dc.description.researchareaCiencias Médicas y de la Educaciónspa
dc.format.extent14 pspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1093/eurheartj/ehab225
dc.identifier.urihttps://repositorio.udes.edu.co/handle/001/6117
dc.language.isoengspa
dc.publisherOxford Academicspa
dc.publisher.placeReino Unidospa
dc.relation.citationendpage3007spa
dc.relation.citationissue31spa
dc.relation.citationstartpage2995spa
dc.relation.citationvolume42spa
dc.relation.citesJackie Bosch, Eva M Lonn, Hyejung Jung, Jun Zhu, Lisheng Liu, Patricio Lopez-Jaramillo, Prem Pais, Denis Xavier, Rafael Diaz, Gilles Dagenais, Antonio Dans, Alvaro Avezum, Leopoldo S Piegas, Alexander Parkhomenko, Kati Keltai, Matyas Keltai, Karen Sliwa, Claus Held, Ronald J G Peters, Basil S Lewis, Petr Jansky, Khalid Yusoff, Kamlesh Khunti, William D Toff, Christopher M Reid, John Varigos, Philip Joseph, Lawrence A Leiter, Salim Yusuf, the Heart Outcomes Prevention Evaluation (HOPE)-3 Investigators, Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants, European Heart Journal, Volume 42, Issue 31, 14 August 2021, Pages 2995–3007, https://doi.org/10.1093/eurheartj/ehab225
dc.relation.indexedScopusspa
dc.relation.ispartofjournalEuropean Heart Journalspa
dc.rightsCopyright © 2021, The Authors, Oxford University Pressspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/spa
dc.sourcehttps://academic.oup.com/eurheartj/article/42/31/2995/6272124?login=truespa
dc.subject.proposalPrimary preventioneng
dc.subject.proposalCardiovascular diseaseeng
dc.subject.proposalStatinseng
dc.titleLowering cholesterol, blood pressure, or both to prevent cardiovascular events: Results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participantsspa
dc.typeArtículo de revistaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dcterms.audienceTodas las Audienciasspa
dspace.entity.typePublication
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
Archivos
Paquete original
Mostrando 1 - 1 de 1
Imagen en miniatura
Nombre:
Lowering cholesterol, blood pressure, or both to prevent cardiovascular events. Results of 8.pdf
Tamaño:
244.25 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Paquete de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
59 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
AGBBA. Artículos de Investigación